Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
domingo, octubre 04
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Gilead Sciences Inc
GILD
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$144.74
-2.76
-1.87%
Últ. Act.: Oct 2, 6:48 PM
$144.91
-2.59
-1.76%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Informe de acciones
Privacy Manager
Gilead Sciences Financials
Gilead Sciences (GILD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est
Gilead Sciences (NASDAQ:GILD) lowers FY2026 GAAP EPS guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) analyst estimate..
Benzinga Newsdesk
PRO
Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est
Gilead Sciences (NASDAQ:GILD) raises FY2026 Adj EPS guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) analyst estimate. Raises FY2026 sales outlook from $30.000 billion-$30.400 billion to $30.100
Benzinga Newsdesk
PRO
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate
Gilead Sciences (NASDAQ:GILD) reported quarterly losses of $(6.75) per share which beat the analyst consensus estimate of $(7.24) by 6.64 percent. This is a 435.82 percent decrease over earnings of $2.01 per share from
Benzinga Newsdesk
PRO
Gilead Sciences Raises FY2026 Sales Guidance from $29.600B-$30.000B to $30.000B-$30.400B vs $30.216B Est
Guidance and OutlookFor the full year 2026, Gilead now expects:(in millions, except per share amounts) May 7, 2026 Guidance Comparison to February 10, 2026 Guidance Low EndHigh EndProduct
Benzinga Newsdesk
PRO
Gilead Sciences Lowers FY2026 Adj EPS Guidance from $8.45-$8.85 to $(1.05)-$(0.65) vs $8.66 Est
GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)(unaudited) (in millions, except percentages and per share amounts) Provided February 10,
Benzinga Newsdesk
PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $6.75-$7.15 to $(3.25)-$(2.85) vs $7.51 Est
GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)(unaudited) (in millions, except percentages and per share amounts) Provided February 10,
Benzinga Newsdesk
